Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ROBERTO J FERNANDEZ

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1275597692
CMS profile
12260
Location
HIALEAH, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$49.05

4 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $49.05 4

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
QOL Medical, LLC $49.05 4

Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ROBERTO J FERNANDEZ

NPI 1275597692 · CMS profile ID 12260

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

HIALEAH, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1275597692?year=2021&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ROBERTO J FERNANDEZ, NPI 1275597692, CMS profile ID 12260. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1275597692?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). ROBERTO J FERNANDEZ, NPI 1275597692, CMS profile ID 12260. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1275597692?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
ROBERTO J FERNANDEZ, NPI 1275597692, CMS profile ID 12260, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1275597692?year=2021&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

4 matching records · $49.05 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 4 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–4 of 4.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
QOL Medical, LLC $13.5811/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833615967 CMS
QOL Medical, LLC $11.4610/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833615965 CMS
QOL Medical, LLC $11.1706/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833615963 CMS
QOL Medical, LLC $12.8406/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833615961 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $34.39 2
PY2021 $49.05 4
PY2022 $195.34 5
PY2023 $131.34 8
PY2024 $146.97 4
PY2025 $266.84 7

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $553,862.43 57
PY2024 Principal investigator $788,899.77 103
PY2023 Principal investigator $383,290.90 39
PY2022 Recipient $4,597.56 1
PY2022 Principal investigator $163,340.52 26
PY2021 Principal investigator $24,299.33 6
PY2020 Principal investigator $21,670.00 9

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

57 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $910.00 12/12/2025 Non-covered Recipient Entity
HOMESTEAD ASSOCIATES IN RESEARCH IN
A Single Dose Open Label Study to Evaluate the Pharmacokinetics of Apalutamide in Subjects With Severe Hepatic Impairment Compared With Subjects With Normal Hepatic Function No dispute reported 06/30/2026 1175370750
Principal investigator 1 Janssen Research & Development, LLC $455.00 12/12/2025 Non-covered Recipient Entity
HOMESTEAD ASSOCIATES IN RESEARCH IN
A Single Dose Open Label Study to Evaluate the Pharmacokinetics of Apalutamide in Subjects With Severe Hepatic Impairment Compared With Subjects With Normal Hepatic Function No dispute reported 06/30/2026 1175370807
Principal investigator 1 Janssen Research & Development, LLC $910.00 12/12/2025 Non-covered Recipient Entity
HOMESTEAD ASSOCIATES IN RESEARCH IN
A Single Dose Open Label Study to Evaluate the Pharmacokinetics of Apalutamide in Subjects With Severe Hepatic Impairment Compared With Subjects With Normal Hepatic Function No dispute reported 06/30/2026 1175370869
Principal investigator 1 Genentech, Inc. $1,000.00 10/29/2025 Non-covered Recipient Entity
HOMESTEAD ASSOCIATES IN RESEARCH INC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211613059
Principal investigator 1 Genentech, Inc. $1,483.00 10/29/2025 Non-covered Recipient Entity
HOMESTEAD ASSOCIATES IN RESEARCH INC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211613066
Principal investigator 1 Genentech, Inc. $1,500.00 10/29/2025 Non-covered Recipient Entity
HOMESTEAD ASSOCIATES IN RESEARCH INC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211613070
Principal investigator 1 Janssen Research & Development, LLC $740.10 10/16/2025 Non-covered Recipient Entity
HOMESTEAD ASSOCIATES IN RESEARCH IN
A Single Dose Open Label Study to Evaluate the Pharmacokinetics of Apalutamide in Subjects With Severe Hepatic Impairment Compared With Subjects With Normal Hepatic Function No dispute reported 06/30/2026 1175370821
Principal investigator 1 Janssen Research & Development, LLC $1,000.10 10/16/2025 Non-covered Recipient Entity
HOMESTEAD ASSOCIATES IN RESEARCH IN
A Single Dose Open Label Study to Evaluate the Pharmacokinetics of Apalutamide in Subjects With Severe Hepatic Impairment Compared With Subjects With Normal Hepatic Function No dispute reported 06/30/2026 1175370833
Principal investigator 1 Janssen Research & Development, LLC $705.10 10/10/2025 Non-covered Recipient Entity
HOMESTEAD ASSOCIATES IN RESEARCH IN
A Single Dose Open Label Study to Evaluate the Pharmacokinetics of Apalutamide in Subjects With Severe Hepatic Impairment Compared With Subjects With Normal Hepatic Function No dispute reported 06/30/2026 1175370691
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $20,880.00 10/07/2025 Non-covered Recipient Entity
Homestead Associates In Research, Inc
An Open-label Study of Ozanimod in Moderate to Severe Ulcerative Colitis in Clinical Practice No dispute reported 06/30/2026 1235996849
Principal investigator 1 Genentech, Inc. $1,500.00 10/03/2025 Non-covered Recipient Entity
HOMESTEAD ASSOCIATES IN RESEARCH INC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211613055
Principal investigator 1 Genentech, Inc. $1,500.00 10/03/2025 Non-covered Recipient Entity
HOMESTEAD ASSOCIATES IN RESEARCH INC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211613063
Principal investigator 1 Bausch Health US, LLC $4,695.50 09/30/2025 Non-covered Recipient Entity
Homestead Associates in in Research, Inc
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224841727
Principal investigator 1 Bausch Health US, LLC $15,200.00 09/24/2025 Non-covered Recipient Entity
Homestead Associates in in Research, Inc
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224841557
Principal investigator 1 Janssen Research & Development, LLC $3,100.00 08/18/2025 Non-covered Recipient Entity
HOMESTEAD ASSOCIATES IN RESEARCH IN C
An Open-label, Single-dose, Parallel-group Study to Evaluate the Effect of HepaticImpairment on the Pharmacokinetics, Safety, and Tolerability of Aticaprant (JNJ-67953964) No dispute reported 06/30/2026 1175370743
Principal investigator 1 Janssen Research & Development, LLC $840.10 08/11/2025 Non-covered Recipient Entity
HOMESTEAD ASSOCIATES IN RESEARCH IN C
A Single Dose Open Label Study to Evaluate the Pharmacokinetics of Apalutamide in Subjects With Severe Hepatic Impairment Compared With Subjects With Normal Hepatic Function No dispute reported 06/30/2026 1175370783
Principal investigator 1 Janssen Research & Development, LLC $1,661.60 07/07/2025 Non-covered Recipient Entity
HOMESTEAD ASSOCIATES IN RESEARCH IN C
A Single Dose Open Label Study to Evaluate the Pharmacokinetics of Apalutamide in Subjects With Severe Hepatic Impairment Compared With Subjects With Normal Hepatic Function No dispute reported 06/30/2026 1175370768
Principal investigator 1 Janssen Research & Development, LLC $531.60 07/07/2025 Non-covered Recipient Entity
HOMESTEAD ASSOCIATES IN RESEARCH IN C
A Single Dose Open Label Study to Evaluate the Pharmacokinetics of Apalutamide in Subjects With Severe Hepatic Impairment Compared With Subjects With Normal Hepatic Function No dispute reported 06/30/2026 1175370773
Principal investigator 1 AstraZeneca Pharmaceuticals LP $962.43 06/23/2025 Non-covered Recipient Entity
HOMESTEAD ASSOCIATES IN RESEARCH, INC
A Phase 2b3 Randomized, Double blind, Placebo controlled Study to Evaluate the Safety and Efficacy of Cotadutide in Participants with Non cirrhotic Non alcoholic Steatohepatitis with Fibrosis No dispute reported 06/30/2026 1185547751
Principal investigator 1 F. Hoffmann-La Roche AG $1,000.00 06/19/2025 Non-covered Recipient Entity
SUN CITY CLINICAL RESEARCH LLC
CD P3: Double-Blind Induction No dispute reported 06/30/2026 1211660182
Principal investigator 1 Janssen Research & Development, LLC $109.04 06/19/2025 Non-covered Recipient Entity
HOMESTEAD ASSOCIATES IN RESEARCH IN C
An Open-label, Single-dose, Parallel-group Study to Evaluate the Effect of HepaticImpairment on the Pharmacokinetics, Safety, and Tolerability of Aticaprant (JNJ-67953964) No dispute reported 06/30/2026 1175370684
Principal investigator 1 Janssen Research & Development, LLC $580.00 06/19/2025 Non-covered Recipient Entity
HOMESTEAD ASSOCIATES IN RESEARCH IN C
An Open-label, Single-dose, Parallel-group Study to Evaluate the Effect of HepaticImpairment on the Pharmacokinetics, Safety, and Tolerability of Aticaprant (JNJ-67953964) No dispute reported 06/30/2026 1175370706
Principal investigator 1 Janssen Research & Development, LLC $525.00 06/13/2025 Non-covered Recipient Entity
HOMESTEAD ASSOCIATES IN RESEARCH IN C
A Single Dose Open Label Study to Evaluate the Pharmacokinetics of Apalutamide in Subjects With Severe Hepatic Impairment Compared With Subjects With Normal Hepatic Function No dispute reported 06/30/2026 1175370699
Principal investigator 1 F. Hoffmann-La Roche AG $2,600.00 06/12/2025 Non-covered Recipient Entity
HOMESTEAD ASSOCIATES IN RESEARCH INC
CD P3: Double-Blind Induction No dispute reported 06/30/2026 1211613005
Principal investigator 1 F. Hoffmann-La Roche AG $11,000.00 06/12/2025 Non-covered Recipient Entity
HOMESTEAD ASSOCIATES IN RESEARCH INC
CD P3: Double-Blind Induction No dispute reported 06/30/2026 1211613008
Principal investigator 1 F. Hoffmann-La Roche AG $2,587.00 06/12/2025 Non-covered Recipient Entity
HOMESTEAD ASSOCIATES IN RESEARCH INC
CD P3: Double-Blind Induction No dispute reported 06/30/2026 1211613010
Principal investigator 1 F. Hoffmann-La Roche AG $3,240.00 06/12/2025 Non-covered Recipient Entity
HOMESTEAD ASSOCIATES IN RESEARCH INC
CD P3: Double-Blind Induction No dispute reported 06/30/2026 1211613014
Principal investigator 1 F. Hoffmann-La Roche AG $973.00 06/12/2025 Non-covered Recipient Entity
HOMESTEAD ASSOCIATES IN RESEARCH INC
CD P3: Double-Blind Induction No dispute reported 06/30/2026 1211613019
Principal investigator 1 ABBVIE INC. $3,000.00 06/03/2025 Non-covered Recipient Entity
HOMESTEAD ASSOCIATES IN RESEARCH
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202488045
Principal investigator 1 ABBVIE INC. $4,200.00 06/03/2025 Non-covered Recipient Entity
HOMESTEAD ASSOCIATES IN RESEARCH
A Multicenter Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1202488047
Principal investigator 1 Bausch Health US, LLC $1,376.59 05/13/2025 Non-covered Recipient Entity
Homestead Associates in in Research, Inc
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224841751
Principal investigator 1 Bausch Health US, LLC $1,648.75 05/07/2025 Non-covered Recipient Entity
Homestead Associates in in Research, Inc
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224841748
Principal investigator 1 AstraZeneca Pharmaceuticals LP $13,790.00 04/16/2025 Non-covered Recipient Entity
WASHINGTON UNIVERSITY EYE CENTER
A Phase 2b3 Randomized, Double blind, Placebo controlled Study to Evaluate the Safety and Efficacy of Cotadutide in Participants with Non cirrhotic Non alcoholic Steatohepatitis with Fibrosis No dispute reported 06/30/2026 1185547753
Principal investigator 1 Janssen Research & Development, LLC $28,313.25 04/14/2025 Non-covered Recipient Entity
HOMESTEAD ASSOCIATES IN RESEARCH IN C
A Single Dose Open Label Study to Evaluate the Pharmacokinetics of Apalutamide in Subjects With Severe Hepatic Impairment Compared With Subjects With Normal Hepatic Function No dispute reported 06/30/2026 1175370671
Principal investigator 1 Janssen Research & Development, LLC $700.00 03/31/2025 Non-covered Recipient Entity
HOMESTEAD ASSOCIATES IN RESEARCH IN C
An Open-label, Single-dose, Parallel-group Study to Evaluate the Effect of HepaticImpairment on the Pharmacokinetics, Safety, and Tolerability of Aticaprant (JNJ-67953964) No dispute reported 06/30/2026 1175370790
Principal investigator 1 Janssen Research & Development, LLC $28,313.25 03/31/2025 Non-covered Recipient Entity
HOMESTEAD ASSOCIATES IN RESEARCH IN C
A Single Dose Open Label Study to Evaluate the Pharmacokinetics of Apalutamide in Subjects With Severe Hepatic Impairment Compared With Subjects With Normal Hepatic Function No dispute reported 06/30/2026 1175370814
Principal investigator 1 Janssen Research & Development, LLC $6,550.00 03/28/2025 Non-covered Recipient Entity
HOMESTEAD ASSOCIATES IN RESEARCH IN C
A Single Dose Open Label Study to Evaluate the Pharmacokinetics of Apalutamide in Subjects With Severe Hepatic Impairment Compared With Subjects With Normal Hepatic Function No dispute reported 06/30/2026 1175370678
Principal investigator 1 Janssen Research & Development, LLC $49,098.61 03/20/2025 Non-covered Recipient Entity
HOMESTEAD ASSOCIATES IN RESEARCH IN C
An Open-label, Single-dose, Parallel-group Study to Evaluate the Effect of HepaticImpairment on the Pharmacokinetics, Safety, and Tolerability of Aticaprant (JNJ-67953964) No dispute reported 06/30/2026 1175370839
Principal investigator 1 Janssen Research & Development, LLC $12,771.68 03/17/2025 Non-covered Recipient Entity
HOMESTEAD ASSOCIATES IN RESEARCH IN C
An Open-label, Single-dose, Parallel-group Study to Evaluate the Effect of HepaticImpairment on the Pharmacokinetics, Safety, and Tolerability of Aticaprant (JNJ-67953964) No dispute reported 06/30/2026 1175370862
Principal investigator 1 Bausch Health US, LLC $3,546.00 03/11/2025 Non-covered Recipient Entity
Homestead Associates in in Research, Inc
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224841735
Principal investigator 1 Janssen Research & Development, LLC $1,100.00 03/10/2025 Non-covered Recipient Entity
HOMESTEAD ASSOCIATES IN RESEARCH IN C
An Open-label, Single-dose, Parallel-group Study to Evaluate the Effect of HepaticImpairment on the Pharmacokinetics, Safety, and Tolerability of Aticaprant (JNJ-67953964) No dispute reported 06/30/2026 1175370847
Principal investigator 1 Janssen Research & Development, LLC $49,098.60 03/06/2025 Non-covered Recipient Entity
HOMESTEAD ASSOCIATES IN RESEARCH IN C
An Open-label, Single-dose, Parallel-group Study to Evaluate the Effect of HepaticImpairment on the Pharmacokinetics, Safety, and Tolerability of Aticaprant (JNJ-67953964) No dispute reported 06/30/2026 1175370713
Principal investigator 1 Bausch Health US, LLC $1,784.23 03/05/2025 Non-covered Recipient Entity
Homestead Associates in in Research, Inc
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224841729
Principal investigator 1 Janssen Research & Development, LLC $49,098.60 03/03/2025 Non-covered Recipient Entity
HOMESTEAD ASSOCIATES IN RESEARCH IN C
An Open-label, Single-dose, Parallel-group Study to Evaluate the Effect of HepaticImpairment on the Pharmacokinetics, Safety, and Tolerability of Aticaprant (JNJ-67953964) No dispute reported 06/30/2026 1175370877
Principal investigator 1 Janssen Research & Development, LLC $720.00 02/17/2025 Non-covered Recipient Entity
HOMESTEAD ASSOCIATES IN RESEARCH IN C
A Single Dose Open Label Study to Evaluate the Pharmacokinetics of Apalutamide in Subjects With Severe Hepatic Impairment Compared With Subjects With Normal Hepatic Function No dispute reported 06/30/2026 1175370761
Principal investigator 1 Genentech, Inc. $2,600.00 02/11/2025 Non-covered Recipient Entity
HOMESTEAD ASSOCIATES IN RESEARCH INC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211613032
Principal investigator 1 Genentech, Inc. $11,000.00 02/11/2025 Non-covered Recipient Entity
HOMESTEAD ASSOCIATES IN RESEARCH INC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211613036
Principal investigator 1 Genentech, Inc. $2,587.00 02/11/2025 Non-covered Recipient Entity
HOMESTEAD ASSOCIATES IN RESEARCH INC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211613040
Principal investigator 1 Genentech, Inc. $973.00 02/11/2025 Non-covered Recipient Entity
HOMESTEAD ASSOCIATES IN RESEARCH INC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211613045
Principal investigator 1 Genentech, Inc. $4,240.00 02/11/2025 Non-covered Recipient Entity
HOMESTEAD ASSOCIATES IN RESEARCH INC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211613050
Principal investigator 1 Janssen Research & Development, LLC $25,918.80 02/05/2025 Non-covered Recipient Entity
HOMESTEAD ASSOCIATES IN RESEARCH IN C
A Single Dose Open Label Study to Evaluate the Pharmacokinetics of Apalutamide in Subjects With Severe Hepatic Impairment Compared With Subjects With Normal Hepatic Function No dispute reported 06/30/2026 1175370734
Principal investigator 1 Janssen Research & Development, LLC $60,059.42 02/03/2025 Non-covered Recipient Entity
HOMESTEAD ASSOCIATES IN RESEARCH IN C
An Open-label, Single-dose, Parallel-group Study to Evaluate the Effect of HepaticImpairment on the Pharmacokinetics, Safety, and Tolerability of Aticaprant (JNJ-67953964) No dispute reported 06/30/2026 1175370853
Principal investigator 1 Bausch Health US, LLC $3,025.34 01/28/2025 Non-covered Recipient Entity
Homestead Associates in in Research, Inc
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224841744
Principal investigator 1 Janssen Research & Development, LLC $66,630.94 01/23/2025 Non-covered Recipient Entity
HOMESTEAD ASSOCIATES IN RESEARCH IN C
A Single Dose Open Label Study to Evaluate the Pharmacokinetics of Apalutamide in Subjects With Severe Hepatic Impairment Compared With Subjects With Normal Hepatic Function No dispute reported 06/30/2026 1175370727
Principal investigator 1 Janssen Research & Development, LLC $1,200.00 01/14/2025 Non-covered Recipient Entity
HOMESTEAD ASSOCIATES IN RESEARCH IN C
A Single Dose Open Label Study to Evaluate the Pharmacokinetics of Apalutamide in Subjects With Severe Hepatic Impairment Compared With Subjects With Normal Hepatic Function No dispute reported 06/30/2026 1175370719
Principal investigator 1 Bausch Health US, LLC $8,300.09 01/07/2025 Non-covered Recipient Entity
Homestead Associates in in Research, Inc
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224841740
Principal investigator 1 Janssen Research & Development, LLC $30,029.71 01/02/2025 Non-covered Recipient Entity
HOMESTEAD ASSOCIATES IN RESEARCH IN C
An Open-label, Single-dose, Parallel-group Study to Evaluate the Effect of HepaticImpairment on the Pharmacokinetics, Safety, and Tolerability of Aticaprant (JNJ-67953964) No dispute reported 06/30/2026 1175370799